In their study focusing specifically on T3 and T4 laryngeal and hypopharyngeal SCCs, Bernstein et al. [72] found that CA-IX expression might confer a more aggressive tumor phenotype, as pre-treatment immunohistochemical CA-IX expression was identified as an adverse prognostic factor for disease-specific survival. Here, CA9 is linked to neoplasm.